The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) reports 2020 data and 2021 features of the Oregon state Prescription Drug Monitoring Program (PDMP).
The name of the Oregon PDMP is the Prescription Drug Monitoring Program (PDMP). It is administered by the Oregon Health Authority, Injury and Violence Prevention. The email address is provided, along with the URLs for the main website and related websites for registering, query, statistics, opioid dashboard, training, and statute/regulation. Contact information is provided for the Program Coordinator and the Program Manager. In 2020, the state population was 4,241,500, and there were 25,974 DEA-registered prescribers and 700 DEA-registered dispensers. The five data transmitters for the PDMP are dispensing practitioners, pharmacy in-state, pharmacy out-of-state, pharmacy in state, and mail order out-of-state pharmacy. Substances monitored are listed in Schedules II-IV and naloxone/narcan dispensations. Eighteen reports are listed as being available from the PDMP. A total of 18 statistical capabilities of the PDMP are also listed. A total of 26 authorized PDMP users encompass the fields of prescribers, dispensers, healthcare professionals, patients, and law enforcement. A staff of eight PDMP employees perform operational, technical, and analytical tasks. Technological capabilities are reported, and patient matching procedures are described. Interstate data-sharing partners are listed. Policies of enrollment and accounts are also described. Training in enrollment and use procedures is provided only to dispensers. Other sections of the report address PDMP queries, unsolicited reports/push notifications, and veterinary policies.
Similar Publications
- The Relationship between Police Contacts for Drug Use-related Crime and Future Arrests, Incarceration, and Overdoses: A Retrospective Observational Study Highlighting the Need to Break the Vicious Cycle
- Prescription Drug Monitoring Program: Oklahoma State Profile (2021)
- Prescription Drug Monitoring Program: New Jersey State Profile (2021)